A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 100
- Registration Number
- NCT03623529
- Locations
- π±πΉ
Investigational Site, Vilnius, Lithuania
A Study of LJPC-501 in Pediatric Patients With Hypotension
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 2
- Registration Number
- NCT03431077
- Locations
- πΊπΈ
Investigational Site, San Antonio, Texas, United States
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 70
- Registration Number
- NCT03395704
- Locations
- πΊπΈ
Investigational Site, San Diego, California, United States
π¬π§Investigative Site, Portsmouth, England, United Kingdom
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 84
- Registration Number
- NCT03381833
- Locations
- π¬π§
Investigative Site, London, United Kingdom
Expanded Access for LJPC-501
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Registration Number
- NCT03245528
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 344
- Registration Number
- NCT02338843
- Locations
- πΊπΈ
Joseph M. Still Research Foundation, Inc., Augusta, Georgia, United States
πΊπΈEastern Idaho Regional Medical Center, Idaho Falls, Idaho, United States
πΊπΈPulmonary Associates of Mobile, PC, Mobile, Alabama, United States
A Phase 2 Extension of Study GCS-100-CS-4003
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Registration Number
- NCT02333955
- Locations
- πΊπΈ
California Institute of Renal Research, La Mesa, California, United States
πΊπΈSouthwest Clinical Research Institute, LLC, Tempe, Arizona, United States
πΊπΈDenver Nephrology, Denver, Colorado, United States
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 375
- Registration Number
- NCT02312050
- Locations
- πΊπΈ
Southeast Renal Research Institute, Chattanooga, Tennessee, United States
πΊπΈClinical Advancement Center, San Antonio, Texas, United States
πΊπΈMountain Kidney & Hypertension, Asheville, North Carolina, United States
A Phase 2 Extension Study of Study GCS-100-CS-4002
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 92
- Registration Number
- NCT02155673
- Locations
- πΊπΈ
California Institute of Renal Research, La Mesa, California, United States
πΊπΈDenver Nephrology, Denver, Colorado, United States
πΊπΈMountain Kidney and Hypertension Associates, PA, Asheville, North Carolina, United States
A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 6
- Registration Number
- NCT01906307
- Locations
- πΊπΈ
Annette C. & Harold C. Simmons Transplant Institute @ Baylor University Medical Center, Dallas, Texas, United States